Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.
| Author | |
|---|---|
| Abstract |
:
The number of studies evaluating the efficacy and safety of third-line molecular-targeted therapy for metastatic renal cell carcinoma (mRCC) is limited. |
| Year of Publication |
:
2018
|
| Journal |
:
International journal of clinical oncology
|
| Date Published |
:
2018
|
| ISSN Number |
:
1341-9625
|
| DOI |
:
10.1007/s10147-018-1241-3
|
| Short Title |
:
Int J Clin Oncol
|
| Download citation |
